Presentation at the Next Generation CAR-TCR Summit (London, UK)
Cartherics Chief Development Officer, Dr Nicholas Boyd
CAR-T immunotherapy has exploded over the last half a decade. It is now a billion-dollar market that is expanding rapidly with over 400+ new cell therapy trials in 2021 alone. But challenges still remain in solid tumours, toxicity management and manufacturing […]
Chief Development Officer, Dr Nicholas Boyd
Cell therapies have the potential to not only be life-saving but curative for a host of diseases. However, inherent limitations in autologous based CAR-T therapy face major roadblocks for mass adoption and therapeutic effects in solid tumour indications.
On Friday 28 January at 7:30 am AEDT Nicholas will discuss the design, […]
By Leigh Dayton, 20 January 2022
Pollyanna Goh – Polly to her friends, family and colleagues – is a specialist’s specialist. For the past decade she has worked in the field of induced pluripotent stem cells (iPSCs). She was such an […]
By Leigh Dayton, 17 January 2022
Cellular immunotherapy is revolutionizing cancer treatment, and off-the-shelf or allogeneic, treatments are beginning to replace technologies developed individually for each patient.
This is good news because the potential of allogeneic therapies is great. They promise to significantly save time and cut costs compared […]
By Leigh Dayton, 4 January 2022
When Cartherics Biomedical Honours student Elizabeth (Liz) Bakaniozos opened an e-mail this month from the Director and CEO of Monash University’s Hudson Institute of Medical Research she was “really surprised and grateful”.
And rightly so. Elizabeth Hartland wrote to advise and congratulate Liz on winning the Hudson Institute Lois Salamonsen Honours […]
By Leigh Dayton, 6 December 2021
When eight Cartherics women first teamed-up to walk or run 4km every day in November and raise funds to support women living with ovarian cancer, they set what they believed were achievable goals. The newly minted CARTeam would collectively move 120 km and raise $500.
They sorely misjudged their efforts. Despite […]
By Leigh Dayton 22 November 2021
It was a challenge that had to be met. “This November, walk or run 4km every day and raise funds to support women living with ovarian cancer,” proposed Ovarian Cancer Australia (OCA), a not-for-profit organisation which supports women […]
By Leigh Dayton
It all began when an e-mail landed in the In-Box of Cartherics’ Executive Assistant Karen Loudon. It was from Ovarian Cancer Australia (OCA), a not-for-profit organisation which supports women diagnosed with ovarian cancer.
The news? “This November, no woman […]
‘Off-the-Shelf’ Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells
Cellular immunotherapy is revolutionizing cancer treatment. However, treatments created from each patient’s cells are complex, costly, and limited by the number and quality of killer T cells that can be isolated from and expanded for re-infusion into each patient.
In this […]
By Leigh Dayton
7 October 2021
According to Cartherics CEO Alan Trounson, taking ideas from the laboratory to the marketplace is a “long and tortuous process”. First-hand experience goes far towards identifying and navigating the hurdles of research translation.
And experience – from pioneering work in IVF and embryonic stem cell science […]
Cartherics’ mission is the development of novel, “off-the-shelf” (allogeneic) immune cell therapy products for the treatment of cancer.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
